In accordance with pharmacologic KRAS inhibition, genetic Kras modulation did not impact the in vitro response of cancer cell lines to deltarasin, as determined by WST-8 IC50 values and ERK activation levels (Figure 3a–e, Supplementary Figures S5 and S6). Here, KRAS is linked to cancer.